Venus Remedies Limited — Meropenem Exporter Profile
Indian Pharmaceutical Exporter · #3 for Meropenem · $41.7M export value · DGFT Verified
Venus Remedies Limited is the #3 Indian exporter of Meropenem with $41.7M in export value and 801 verified shipments. Venus Remedies Limited holds a 18.0% market share in Meropenem exports across 41 countries. The company exports 29 pharmaceutical products worth $86.4M across 6 therapeutic categories.
Venus Remedies Limited — Meropenem Export Profile: Buyers & Destinations
Where Does Venus Remedies Limited Export Meropenem?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SAUDI ARABIA | $4.5M | 194 | 25.4% |
| GERMANY | $3.6M | 187 | 20.5% |
| PERU | $1.5M | 31 | 8.4% |
| AUSTRALIA | $1.1M | 25 | 6.1% |
| HUNGARY | $1.0M | 24 | 5.9% |
| MEXICO | $691.2K | 20 | 3.9% |
| BAHRAIN | $541.0K | 16 | 3.0% |
| SUDAN | $537.2K | 13 | 3.0% |
| SOUTH AFRICA | $403.7K | 13 | 2.3% |
| ISRAEL | $395.1K | 13 | 2.2% |
Venus Remedies Limited exports Meropenem to 47 countries. The largest destination is SAUDI ARABIA accounting for 25.4% of Venus Remedies Limited's Meropenem shipments, followed by GERMANY (20.5%) and PERU (8.4%). These destinations reflect Venus Remedies Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Meropenem from Venus Remedies Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| VENUS PHARMA GMBH | GERMANY | $2.3M | 144 |
| S T C | SAUDI ARABIA | $2.3M | 95 |
| SALEHIYA TRADING COMPANY | SAUDI ARABIA | $1.3M | 64 |
| E P H K | HUNGARY | $1.0M | 24 |
| S T C SALEHIYA TRADING | SAUDI ARABIA | $714.9K | 28 |
| VPG VENUS PHARMA GMBHAM BAHNHOF | GERMANY | $621.9K | 15 |
| G H | AUSTRALIA | $569.4K | 13 |
| V P G | GERMANY | $558.9K | 22 |
| O S.A.C. | PERU | $450.0K | 9 |
| SAMASU MEDICAL & EDUCATIONAL | SUDAN | $397.1K | 10 |
Venus Remedies Limited supplies Meropenem to 154 buyers globally. The largest buyer is VENUS PHARMA GMBH (GERMANY), followed by S T C (SAUDI ARABIA) and SALEHIYA TRADING COMPANY (SAUDI ARABIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Meropenem Export Value and How Much Does Venus Remedies Limited Contribute?
India exported $80.5M worth of Meropenem through 3,658 shipments from 401 suppliers to 134 countries, serving 966 buyers globally. Venus Remedies Limited contributes $41.7M to this total, accounting for 18.0% of India's Meropenem exports. Venus Remedies Limited ships Meropenem to 47 countries through 154 buyers.
What Is the Average Shipment Value for Venus Remedies Limited's Meropenem Exports?
Venus Remedies Limited's average Meropenem shipment value is $52.1K per consignment, based on 801 shipments totaling $41.7M. The largest destination is SAUDI ARABIA (25.4% of Venus Remedies Limited's Meropenem exports).
How Does Venus Remedies Limited Compare to Other Indian Meropenem Exporters?
Venus Remedies Limited ranks #3 among 401 Indian Meropenem exporters with a 18.0% market share. The top 3 exporters are VENUS REMEDIES LIMITED ($40.0M), EUGIA PHARMA SPECIALITIES LIMITED ($17.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($10.3M). Venus Remedies Limited processed 801 shipments to 41 destination countries.
What Meropenem Formulations Does Venus Remedies Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MEROPENEM 1.0 GM POWDER FOR SOLUTION FOR | $3.1M | 111 |
| MEROPENEM 500 MG POWDER FOR SOLUTION FOR | $1.7M | 56 |
| MEROPENEM 1.0GM POWDER FOR SOLUTION FOR | $409.5K | 10 |
| RONEM 500 MG (MEROPENEM POWDER FOR SOLUTION FOR INJECTION) MOOWR SCHEME VIDE LICENSE NO.- 03/2023 -LUDHIANANOS | $300.0K | 6 |
| MEROPENEM 1.0 GM POWDER FOR SOLUTION FORINJECTION OR INFUSION (RONEM 1000 MG) | $212.5K | 10 |
| MEROPENEM 1 0 GM POWDER FOR SOLUTION FORINJECTION OR INFUSION RONEM 1000 MG | $195.4K | 10 |
| MEROPENEM 1.0 GM POWDER FOR SOLUTION FORINJECTION OR INFUSION (MEROPENEM VENUSPHARMA 1 GM) | $150.0K | 3 |
| MEROPENEM 1.0 GM POWDER FOR SOLUTION FORINJECTION OR INFUSION MEROPENEM VENUSPHARMA 1.0 GM | $150.0K | 3 |
| MEROPENEM GH 1000 MG MEROPENEM (AS TRIHYDRATE) 1000 MG POWDER FOR INJECTION 1VIAL CONTAINS: MEROPENEM (AS TRIHYDRATE)NOS | $150.0K | 3 |
| RONEM 1000 MG (MEROPENEM 1 G POWDER FORSOLUTION FOR INJECTION OR INFUSION) (MOOWR SCHEME VIDE LICENSE NO.-03/2023 -LDH)NOS | $150.0K | 3 |
Venus Remedies Limited exports 441 distinct Meropenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MEROPENEM 1.0 GM POWDER FOR SOLUTION FOR with 111 shipments worth $3.1M.
Regulatory Requirements: Exporting Meropenem to Key Markets
What Venus Remedies Limited must comply with to export Meropenem to its top destination countries
Germany — BfArM/EMA
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Venus Remedies Limited Compare to Nearest Meropenem Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | VENUS REMEDIES LIMITED ★ | $40.0M | 801 | 41 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $17.1M | 341 | 18 | $50.0K |
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $10.3M | 206 | 16 | $50.0K |
Venus Remedies Limited ranks #3 among 401 Indian Meropenem exporters. Average shipment value of $50.0K compared to the market average of $200.8K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Meropenem Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 504 | 13.8% |
| DELHI AIR | 494 | 13.5% |
| SAHAR AIR | 256 | 7.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 246 | 6.7% |
| NHAVA SHEVA SEA (INNSA1) | 233 | 6.4% |
| CMA CGM LOGISTICS PARK ICD (INCPL6) | 198 | 5.4% |
| Delhi Air | 103 | 2.8% |
| DHANNAD ICD (INDHA6) | 94 | 2.6% |
What Other Advanced Antibiotics Products Does Venus Remedies Limited Export?
Venus Remedies Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Venus Remedies Limited's Meropenem Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Venus Remedies. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for exports to Europe and the Americas. Such disruptions necessitate strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost-effectiveness.
Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to strengthen their presence in the U.S. market. India now supplies 40% of the U.S.'s generic drug needs, reflecting a growing reliance on Indian manufacturers. (ibef.org) Venus Remedies' recent QIDP designation from the U.S. FDA for VRP-034 positions the company favorably to leverage this opportunity, potentially enhancing its market share in the U.S.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains critical. Venus Remedies' renewal of the EU-GMP certification indicates their proactive approach to meeting stringent EU regulations, thereby ensuring continued access to European markets. (business-standard.com)
Venus Remedies Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for pharmaceutical exporters. Venus Remedies has demonstrated a consistent commitment to quality, as evidenced by multiple GMP certifications. In addition to the EU-GMP renewal, the company secured GMP certification from Moldova's Ministry of Health in January 2025, covering their antibiotic-carbapenem manufacturing facility. (apnnews.com) Furthermore, the renewal of Ukrainian GMP certification in May 2025 for their Baddi facility underscores their adherence to global quality standards. (apnnews.com)
These certifications not only facilitate market access but also enhance the company's reputation as a reliable supplier of high-quality pharmaceuticals. In an industry where regulatory compliance is closely scrutinized, Venus Remedies' proactive measures position them favorably among global competitors.
About Venus Remedies Limited
Venus Remedies Limited exports 29 products worth $86.4M. Beyond Meropenem, top products include Imipenem, Enoxaparin, Ceftriaxone, Paclitaxel, Carboplatin. View the complete Venus Remedies Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Meropenem — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Meropenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Venus Remedies Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 834 individual customs records matching Venus Remedies Limited exporting Meropenem, covering 441 formulations to 47 countries via 154 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 134+ countries, 966+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Meropenem Export Data from Venus Remedies Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Venus Remedies Limited's Meropenem exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Venus Remedies Limited
Full Company Profile →
29 products · $86.4M total trade · 6 categories
Meropenem Stats
Company Overview
Top Products by Venus Remedies Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Venus Remedies Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Meropenem. For current shipment-level data, contact TransData Nexus.